The Oncology Institute is positioned for substantial growth, focusing on its value-based care model within the expanding oncology market. The company's model aims to improve care quality and reduce costs. TOI's revenue growth is demonstrated by its increase in value-based members and expansion into new markets.
TOI is an early market leader in the oncology market.
The company operates with a proven and scalable model.
TOI is well-capitalized, employing a disciplined deployment strategy.
The company aims to provide high-quality, affordable care to more patients through platform growth.
The Oncology Institute projects revenue between $400 million and $415 million, gross profit between $68 million and $79 million, and adjusted EBITDA between $(8) million and $(18) million for the year 2024.
Visualization of income flow from segment revenue to net income